Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Chinese Journal of New Drugs ; 31(10):972-977, 2022.
Article in Chinese | EMBASE | ID: covidwho-1894105


Objective: To explore the implementation and management measures of drug clinical trials during the period of COVID-19 epidemic, protect the safety and rights of subjects, ensure the smooth implementation of clinical trials, and provide reference and suggestions for the management work of clinical trial institutions. Methods: According to the requirements of COVID-19 epidemic prevention and control policies and the national guiding principles for drug clinical trial management, combining the experience of our hospital, we optimized the working process and proposed management measures in four aspects including project and personnel management, subject follow-up management, drug distribution management, and communication between all parties involved in clinical trials. Results and conclusions: During the period of COVID-19 epidemic, our hospital has taken a series of measures which ensured the smooth implementation of more than 200 drug clinical trials and protected the safety and rights of subjects and researchers.

Informs Journal on Applied Analytics ; : 16, 2022.
Article in English | Web of Science | ID: covidwho-1886976


This study examines the impact of coronavirus disease 2019 (COVTD-19) test accuracy (i.e., sensitivity and specificity) on the progression of the pandemic under two scenarios of limited and unlimited test capacity. We extend the classic susceptible-exposed-infectious-recovered model to incorporate test accuracy and compare the progression of the pandemic under various sensitivities and specificities. We find that high-sensitivity tests effectively reduce the total number of infections only with sufficient testing capacity. Nevertheless, with limited test capacity and a relatively high cross-infection rate, the total number of infected cases may increase when sensitivity is above a certain threshold. Despite the potential for higher sensitivity tests to identify more infected individuals, more false positive cases occur, which wastes limited testing capacity, slowing down the detection of infected cases. Our findings reveal that improving test sensitivity alone does not always lead to effective pandemic control, indicating that policymakers should balance the trade-off between high sensitivity and high false positive rates when designing containment measures for infectious diseases, such as COVID-19, particularly when navigating limited test capacity.

Zhonghua Yu Fang Yi Xue Za Zhi ; 55(2): 288, 2021 02 06.
Article in Chinese | MEDLINE | ID: covidwho-1468520

COVID-19 , Aged , Humans , SARS-CoV-2
Remote Sensing ; 13(9):18, 2021.
Article in English | Web of Science | ID: covidwho-1244107


Air quality is strongly influenced by both local emissions and regional transport. Atmospheric chemical transport models can distinguish between emissions and regional transport sources in air pollutant concentrations. However, quantifying model inventories is challenging due to emission changes caused by the recent strict control measures taken by the Chinese government. In this study, we use NO2 column observations from the Tropospheric Monitoring Instrument to retrieve top-down nitrogen oxide (NOX) emissions and quantify the contributions of local emissions and regional transport to NOx in Beijing (BJ), from 1 November 2018 to 28 February 2019 (W_2018) and 1 November 2019 to 29 February 2020 (W_2019). In W_2018 and W_2019, the BJ bottom-up NOX emissions from the multi-resolution emission inventory for China in 2017 were overestimated by 11.8% and 40.5%, respectively, and the input of NOX from other cities to BJ was overestimated by 10.9% and 51.6%, respectively. The simulation using our adjusted inventory exhibited a much higher spatial agreement (slope = 1.0, R-2 = 0.79) and reduced a mean relative error by 45% compared to those of bottom-up NOX emissions. The top-down inventory indicated that (1) city boundary transport contributes approximately 40% of the NOX concentration in BJ;(2) in W_2019, NOX emissions and transport in BJ decreased by 20.4% and 17.2%, respectively, compared to those of W_2018;(3) in W_2019, NOX influx substantially decreased (-699 g/s) in BJ compared to that of W_2018 despite negative meteorological conditions that should have increased NOx influx by +503 g/s. Overall, the contribution of intercity input to NOx in BJ has declined with decreasing emissions in the surrounding cities due to regional cooperative control measures, and the role of local emissions in BJ NOx levels was more prominent. Our findings indicate that local emissions may play vital roles in regional center city air quality.

BMC Infectious Diseases ; 21(1):397, 2021.
Article in English | MEDLINE | ID: covidwho-1209891


BACKGROUND: Coronavirus disease 2019 (COVID-19) has emerged as a major global health threat with a great number of deaths worldwide. Despite abundant data on that many COVID-19 patients also displayed kidney disease, there is limited information available about the recovery of kidney disease after discharge. METHODS: Retrospective and prospective cohort study to patients with new-onset kidney disease during the COVID-19 hospitalization, admitted between January 28 to February 26, 2020. The median follow-up was 4 months after discharge. The follow-up patients were divided into the recovery group and non-recovery group. Descriptive statistics and between-groups comparison were used. RESULTS: In total, 143 discharged patients with new-onset kidney disease during the COVID-19 hospitalization were included. Patients had a median age was 64 (IQR, 51-70) years, and 59.4% of patients were men. During 4-months median follow-up, 91% (130 of 143) patients recovered from kidney disease, and 9% (13 of 143) patients haven't recovered. The median age of patients in the non-recovery group was 72 years, which was significantly higher than the median age of 62 years in the recovery group. Discharge serum creatinine was significantly higher in the non-recovery group than in the recovery group. CONCLUSIONS: Most of the new-onset kidney diseases during hospitalization of COVID-19 patients recovered 4 months after discharge. We recommend that COVID-19 patients with new-onset kidney disease be followed after discharge to assess kidney recovery, especially elderly patients or patients with high discharge creatinine.